

Pheochromocytoma - Pipeline Review, H2 2020

<https://marketpublishers.com/r/PFD4C088E8FEN.html>

Date: October 2020

Pages: 161

Price: US\$ 2,000.00 (Single User License)

ID: PFD4C088E8FEN

Abstracts

Pheochromocytoma - Pipeline Review, H2 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Pheochromocytoma - Pipeline Review, H2 2020, provides an overview of the Pheochromocytoma (Oncology) pipeline landscape.

Pheochromocytoma is a rare, usually non-cancerous (benign) tumor that develops in cells in the center of an adrenal gland. Symptoms include high blood pressure, severe headache, tremors, shortness of breath and constipation. Risk factors include multiple endocrine neoplasia type II (MEN), Von Hippel-Lindau disease (VHL) and neurofibromatosis 1 (NF1).

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Pheochromocytoma - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Pheochromocytoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Pheochromocytoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Pheochromocytoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 11, 3 and 1 respectively.

Pheochromocytoma (Oncology) pipeline guide helps in identifying and tracking

emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Pheochromocytoma (Oncology).

The pipeline guide reviews pipeline therapeutics for Pheochromocytoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Pheochromocytoma (Oncology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Pheochromocytoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for

Pheochromocytoma (Oncology)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Pheochromocytoma (Oncology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Pheochromocytoma (Oncology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction

Pheochromocytoma - Overview

Pheochromocytoma - Therapeutics Development

Pheochromocytoma - Therapeutics Assessment

Pheochromocytoma - Companies Involved in Therapeutics Development

Pheochromocytoma - Drug Profiles

Pheochromocytoma - Dormant Projects

Pheochromocytoma - Discontinued Products

Pheochromocytoma - Product Development Milestones

Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Pheochromocytoma, H2 2020
Number of Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020
Number of Products by Stage and Target, H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Pheochromocytoma - Pipeline by Advanced Accelerator Applications SA, H2 2020
Pheochromocytoma - Pipeline by AstraZeneca Plc, H2 2020
Pheochromocytoma - Pipeline by Enterome Bioscience SA, H2 2020
Pheochromocytoma - Pipeline by Exelixis Inc, H2 2020
Pheochromocytoma - Pipeline by Fujifilm Holdings Corp, H2 2020
Pheochromocytoma - Pipeline by Gibson Oncology LLC, H2 2020
Pheochromocytoma - Pipeline by Ipsen SA, H2 2020
Pheochromocytoma - Pipeline by Jubilant DraxImage Inc, H2 2020
Pheochromocytoma - Pipeline by Lixte Biotechnology Holdings Inc, H2 2020
Pheochromocytoma - Pipeline by Oncoceutics Inc, H2 2020
Pheochromocytoma - Pipeline by Pfizer Inc, H2 2020
Pheochromocytoma - Pipeline by Tarveda Therapeutics Inc, H2 2020
Pheochromocytoma - Pipeline by Vyriad Inc, H2 2020
Pheochromocytoma - Dormant Projects, H2 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Pheochromocytoma, H2 2020

Number of Products under Development by Companies, H2 2020

Number of Products by Top 10 Targets, H2 2020

Number of Products by Stage and Top 10 Targets, H2 2020

Number of Products by Top 10 Mechanism of Actions, H2 2020

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020

Number of Products by Routes of Administration, H2 2020

Number of Products by Stage and Routes of Administration, H2 2020

Number of Products by Molecule Types, H2 2020

Number of Products by Stage and Molecule Types, H2 2020

I would like to order

Product name: Pheochromocytoma - Pipeline Review, H2 2020

Product link: <https://marketpublishers.com/r/PFD4C088E8FEN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/PFD4C088E8FEN.html>